Introduction
SIBIONICS, founded in 2015, transforms diabetes management with the GS1 Continuous Glucose Monitoring (CGM) System. It serves over 1,000,000 users globally and gained EU MDR CE certification in 2023 for Europe. This blog explores the GS1’s features, benefits, and recent advancements for effective glucose monitoring.
What is the SIBIONICS GS1 Continuous Glucose Monitor?
The GS1 CGM offers real-time glucose tracking for 14 days without scanning or finger-pricking. A small sensor on the arm, a transmitter, and a smartphone app provide seamless monitoring. It’s calibration-free, waterproof (IP28), and comfortable for daily activities like bathing or exercising.
Key Features
- 14-Day Sensor: Monitors glucose continuously for two weeks.
- Calibration-Free: Factory-calibrated sensors eliminate fingerstick calibrations.
- Real-Time Alerts: Customizable alarms for high or low glucose levels.
- User-Friendly App: Displays trends, logs meals, and shares data.
- High Accuracy: MARD of 8.83% overall, 9.15% for Type 1 diabetes.
- Waterproof Design: IP28 rating supports daily activities.
- Painless Application: Dual spring applicator ensures quick, comfortable insertion.
Why Choose SIBIONICS GS1?
The GS1 simplifies diabetes management with accurate, user-friendly technology. Its benefits include:
- Better Control: Real-time data aids diet and medication decisions.
- Safety Alerts: Warns of high or low glucose levels.
- Easy Integration: App features streamline daily use.
- Cost-Effective: Long sensor life reduces expenses.
- Trusted Globally: Used by 600,000 people and 1,600 hospitals.
However, the GS1 requires fingerstick confirmation for insulin dosing, which some Type 1 diabetes users find limiting.
Latest Research and Advancements
SIBIONICS advances CGM technology through ongoing research and innovation.
Research Highlights
- Accuracy: Clinical trials show a MARD of 8.83%, with 9.15% for Type 1 diabetes users.
- CE Certification (2023): GS1 earned EU approval for safety and efficacy.
- Advanced Sensors: Second-generation sensors ensure high stability and consistency.
- Hospital Use: Over 1,600 hospitals globally adopt GS1, with 6,000,000 units produced yearly.
Recent and Upcoming Advancements
- App Updates (2024): Version 01.08 adds meal logging, barcode scanning, and lock-screen glucose display.
- Influencer Event (March 2024): Florence event announced GS2 CGM, GS ECO transmitter, and a glucose-ketone monitor.
- SiWatch (2024): Wrist-worn device for phone-free glucose monitoring.
- KS1 Ketone Monitor: Supports ketosis with 14-day usage and diet guidance.
- AI Integration: AI-DR system aids diabetic retinopathy diagnosis in China.
- Restructuring (October 2024): Online store paused for strategic upgrades, with plans for improved products.
- Funding (2022): Raised $71.7M for AI-driven medical device development.
Future Directions
SIBIONICS aims to enhance accessibility and affordability. Plans include global expansion, better app features, longer-lasting sensors, and AI innovations.
Real-World Impact
Users value the GS1’s simplicity and reliability for daily glucose management. Healthcare providers use its reports for better treatment plans. The discreet, painless design reduces monitoring stigma, supporting active lifestyles.
Challenges and Considerations
- Treatment Limits: Fingerstick confirmation needed for insulin dosing.
- Cost: Priced at £56, considered expensive by some, though discounts help.
- Availability: 2024 restructuring may temporarily limit access.
Conclusion
The SIBIONICS GS1 CGM empowers users with accurate, convenient glucose monitoring. Its 14-day sensor, intuitive app, and alerts enhance diabetes management. With advancements like GS2 and SiWatch, SIBIONICS leads CGM innovation. Visit www.sibionicscgm.com or email [email protected] for updates. Consult healthcare providers before use.
Note: Always consult a healthcare provider before using any CGM system.
Add Comment